The company has reported positive findings from analysis conducted combining its V-Go wearable basal plus bolus insulin delivery device with a weekly physician-driven and simplified prandial-focused insulin titration algorithm.
According to the company, achievement of glycemic targets occurred in 2/3 of patients and patient reported hypoglycemia was decreased by study end utilizing this therapeutic approach to insulin management.
Texas Star Adult Medicine’s Dr.
Daily four-point self-monitored blood glucose profiles have been used for weekly V-Go titration decisions.
Bolus up-titration was recommended weekly when two-hour postprandial averages exceeded 170 mg/dl and down-titrated when 2-hour postprandial averages were below 100 mg/dl, based on the algorithm.
Around 15 patients in the proof of concept study have been assessed after four months of V-Go use with insulin dose adjustments occurring predominantly during the first three weeks.
An A1C target of 7.5% or lower was observed in 67% of patients, while a mean significant A1C reduction of 1.6 was achieved with a significant decrease in the mean total daily dose of insulin.
V-Go wearable insulin delivery device is a wearable and basal-bolus insulin delivery device for patients with type 2 diabetes, which allows patients to administer a continuous preset basal rate of insulin over 24 hours.
Valeritas president and CEO John Timberlake said: “This proof-of-concept study demonstrates that a simplified prandial or bolus focused weekly insulin titration algorithm in patients with Type 2 diabetes (T2D) prescribed V-Go can be used effectively and safely, leading to significantly improved glycemic control while also lowering the mean total daily insulin dose of insulin.”
Image: The V-Go device along with insulin titration algorithm has decreased A1C and insulin requirements in patients with type 2 diabetes. Photo: courtesy of suphakit73 / FreeDigitalPhotos.net.
